查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2004208

DNA定序市场：2026-2032年全球市场预测（按服务类型、技术类型、样本类型、应用和最终用户划分）

DNA Sequencing Market by Offerings, Technology Type, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，DNA定序市场价值将达到 212.7 亿美元，到 2026 年将成长至 257.2 亿美元，到 2032 年将达到 836.9 亿美元，年复合成长率为 21.61%。

主要市场统计数据
基准年 2025 212.7亿美元
预计年份：2026年 257.2亿美元
预测年份 2032 836.9亿美元
复合年增长率 (%) 21.61%

2025年DNA定序现况：在政策和供应链变化中，从创新科学到可扩展的临床实践

DNA定序处于基础科学、临床诊断和数据驱动公共卫生三者的交汇点。到2025年，该领域将迎来转折点，其应用范围将从主要面向研究的技术扩展到临床医学、农业科学、环境监测和安全等领域。这项转变的驱动力来自于读取准确性、通量和工作流程自动化的持续改进，以及资讯科学的进步和监管及报销环境的日趋成熟。

揭示正在重塑定序的变革性变化：长读长定序、即时奈米孔定序、多体学、人工智慧生物资讯学和严格的临床检验。

最显着的变化在于各种定序模式在准确性、速度和成本方面的趋于一致，使得终端使用者能够根据自身面临的生物学挑战而非传统限制来选择平台。合成短读定序凭藉其高保真化学反应系统和能够改善Q值分布并减少对PhiX依赖性的软体，正在拓展其临床应用范围，并简化基于计数的检测和全基因组分析。近期平台的更新增强了多体学功能，并提供了低通量单流池配置，在不牺牲数据品质的前提下降低了专业实验室的进入门槛。这反映了一种更广泛的趋势，即根据实际样本量和周转需求来选择合适的仪器。

评估 2025 年美国关税对供应链定序、定价、跨境贸易和策略供应商多元化的累积影响。

2025年，贸易政策将成为定序买家成本、前置作业时间和平台选择的主要决定因素。 2025年伊始，美国政府就面临着持续实施的301条款措施以及2024年底宣布的对具有战略意义的重要投入品加征关税的阴影。这些投入品包括钨製品、晶圆和多晶硅等材料，将于2025年1月1日生效，并流入光学、微电子和特殊元件领域，这些领域广泛用于设备、流动池和製造设备。虽然这些措施并非专门针对基因组学，但它们将对上游供应链和供应商定价产生连锁反应。

整体而言，2025 年的这些关税趋势正在重塑品类层面的经济格局：

虽然设备和平台的标价相对于运输和安装成本相对稳定，但当组件、光学元件或电子元件需要缴纳关税时，总拥有成本就会增加。采用单流池或其他小规模配置的供应商，无意中为买家提供了在预算週期不确定的情况下逐步提高产能的柔软性。

解读产品、技术、样品、应用和最终用户等关键细分市场洞察，从而更有信心地做出产品组合决策。

从产品线观点来看，重点正从独立仪器转向基于化学、供应连续性和资讯学的整合系统。虽然仪器和平台定义了核心功能，但决定实际效用的因素正日益转向耗材和试剂——例如，用于在样本质量波动的情况下稳定文库的酶和缓衝液，用于支持靶向或伙伴关係子测序的引物和探针，以及针对最新化学反应优化的全套测序试剂盒。服务正在重组为生命週期合作伙伴关係。具体而言，这些服务包括：合约定定序以应对临时需求高峰；生物资讯学和数据分析服务，将原始数据（线索）转化为临床或研究报告；以及技术支援和维护，以确保仪器符合认证标准。软体在整合整个系统中发挥核心作用，从机载碱基识别到云端原生二次分析和报告，并提供审计追踪以满足监管机构和支付方的要求。

当前主要区域趋势：美洲、欧洲、中东、非洲和亚太地区将如何影响采用率、取得率和合规性？

区域趋势既决定机会也决定风险。在美洲，美国正在引领临床应用的趋势。原定于2024年实施的加强监管、将检查室自建检测（LDT）纳入医疗设备监管的倡议，于2025年3月被联邦法院驳回，目前正被撤回，这既带来了一丝慰藉，也带来了一丝不确定性。儘管如此，许多医院和诊断检查室仍在加强其品管系统和文件记录，他们预计联邦政府和保险公司将在一定程度上主导标准化进程。同时，被誉为伴随诊断的综合基因组分析试剂盒正在推动肿瘤检测向区域和地方中心分散化，尤其是在早期采用者证明了其营运可行性和符合保险公司要求的情况下。在加拿大和拉丁美洲市场，预算限制与群体基因组分析的雄心壮誌之间存在着平衡，当地服务供应商通常被用来应对关税和外汇波动造成的成本波动。

主要企业提出的未来：平台蓝图、监管里程碑、伙伴关係以及围绕临床级工作流程的竞争。

近期公司层面的发展为我们了解竞争对手的未来走向提供了重要线索。其中一项最重要的公司里程碑事件是2024年中期完成的一项大规模资产剥离。此举解决了监管方面的担忧，使核心定序业务能够重新专注于平台开发和临床伙伴关係。此后，该供应商对其旗舰高通量产品线进行了升级，推出了单流式细胞选项、可提高产量并减少对PhiX依赖性的软体版本，以及专为多组体学工作负载设计的新型试剂盒。此外，该公司还拥有获得FDA已通过核准的综合基因组分析试剂盒（体外诊断试剂盒，被誉为所有癌症的伴随诊断试剂），这使得该公司能够支持从学术机构到区域医疗系统的集中式和分散式肿瘤学模式。

为产业领导者提供的实用指导：降低供应风险、加速证据收集、协调合规性，并将定序创新转化为成果。

首先，关税应被视为长期因素，而非突如其来的衝击。制定一个涵盖设备、流动池和耗材的18-24个月滚动采购计划，并纳入基于情境的到货成本模型，该模型应包含关于关税税率、运输和安装前置作业时间的明确假设。对于关键耗材（例如引子和探针、酵素和缓衝液以及定序盒），除了价格指数挂钩定价外，还应寻找替代供应商，并协商在关税区变更时触发的应急条款。在临床环境中，应调整安全库存，使其与认证和验证週期保持一致，以避免停机。

本执行摘要的编写方法：采用严谨的调查方法，结合一手资料、监管审查和交叉检验的二手资料。

本执行摘要整合了透过混合方法收集的洞见，该方法着重于深度、三角验证和可追溯性。主要研究包括对北美、欧洲和亚太地区的定序平台所有者、临床实验室主任、学术核心设施负责人、转化研究人员、CRO高管和生物资讯架构师进行结构化和半结构化访谈。这些访谈重点在于平台选择标准、使用改进试剂后的运作性能、验证和认证实践、关税和出口管制带来的采购限制，以及生物资讯学与电子健康记录（EHR）之间不断发展的合作。

总结整体情况：为什么定序正在进入持续的实际应用阶段，以及如何在波动和政策变化中做出明智的投资。

DNA定序已进入持续应用阶段。这项科学日趋成熟，整合了各种平台、化学试剂和资讯学，建构出检验的工作流程，能够以过去难以想像的速度和精确度解答临床和研究问题。长读长定序方法已与短读长定序方法并驾齐驱，奈米孔定序平台正从现场应用扩展到规范化的工作流程，而全面的基因组分析也已克服监管方面的障碍，从而实现了肿瘤检测的去中心化。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 DNA定序市场：依产品/服务分类

  • 耗材和试剂
    • 酵素和缓衝液
    • 引子和探针
    • 定序盒
  • 设备和平台
    • DNA定序仪
    • 样品製备系统
    • PCR装置
    • 流通池和滤芯硬体
  • 服务
    • 合约定序
    • 生物资讯学和数据分析服务
    • 技术支援和维护
  • 软体

第九章：DNA定序市场：依技术类型划分

  • 次世代定序（NGS）
    • 合成定定序
    • 奈米孔定序
    • 离子半导体定序
  • 桑格定序
  • 第三代定序（TGS）
  • 表观遗传定序
    • 亚硫酸氢盐定序
    • ChIP定序

第十章：依检体类型分類的DNA定序市场

  • 人类检体
    • 血
    • 唾液和口腔黏膜拭子
    • 尿
    • 细胞中的游离DNA
    • 组织
    • 电浆
  • 动物检体
  • 植物样品
    • 叶子
    • 根
    • 种子
  • 微生物样本
    • 细菌
    • 病毒
    • 真菌
    • 古菌
  • 环境样品

第十一章：DNA定序市场：依应用领域划分

  • 临床诊断
    • 肿瘤学
    • 感染疾病的诊断
    • 罕见疾病和遗传疾病的检测
    • 生殖医学和产前检查
    • 新生儿筛检
  • 出于研究目的
    • 基因组学和转录组学
    • 功能基因体学
    • 表观遗传学研究
  • 药物发现和药物开发
    • 生物标记发现
    • 伴随诊断
    • 目标识别与检验
  • 农业基因组学
    • 植物育种和性状发现
    • 作物病原体监测
  • 法医学与安全
    • 个人识别
    • 刑事调查
    • 识别灾难受害者
  • 环境与元基因组学研究

第十二章 DNA定序市场：依最终用户划分

  • 学术和研究机构
    • 政府附属研究机构
    • 大学研究实验室
  • 合约研究机构
  • 医院和诊断检查室
  • 製药和生物技术公司

第十三章：DNA定序市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 DNA定序市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 DNA定序市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国DNA定序市场

第十七章：中国DNA定序市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 10x Genomics, Inc.
  • Abbott Laboratories
  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • Azenta, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • BioChain Institute Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • Eppendorf SE
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • Genomics England
  • Genscript Biotech Corporation
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Laboratory Corporation of America Holdings
  • Macrogen Inc.
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Novartis AG
  • Novogene Co, Ltd.
  • Oxford Nanopore Technologies PLC
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Sartorius AG
  • Shimadzu Corporation
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience Corporation
Product Code: MRR-450A0628CCF5

The DNA Sequencing Market was valued at USD 21.27 billion in 2025 and is projected to grow to USD 25.72 billion in 2026, with a CAGR of 21.61%, reaching USD 83.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 21.27 billion
Estimated Year [2026] USD 25.72 billion
Forecast Year [2032] USD 83.69 billion
CAGR (%) 21.61%

Illuminating the state of DNA sequencing in 2025: from disruptive science to scalable clinical practice amid shifting policy and supply chains

DNA sequencing sits at the nexus of discovery science, clinical diagnostics, and data-driven public health. In 2025, the field has crossed a threshold from primarily research-oriented technology to a widening footprint in clinical care, agriscience, environmental surveillance, and security. This transition is powered by relentless improvements in read accuracy, throughput, and workflow automation, paired with better informatics and a maturing regulatory and reimbursement context.

At the same time, operating conditions are more complex than at any point in the last decade. Supply chains have been reshaped by tariffs and export controls, data flows are governed by evolving privacy regimes, and clinical validation standards are tightening even as some rules are being re-written by courts and legislators. These cross-currents demand that leaders rethink platform strategy, inventory policies, informatics architectures, and partnerships.

What differentiates the current landscape is that technology progress and policy dynamics are unfolding simultaneously. Sequencing chemistry and optics are leaping forward while long-read modalities gain clinical traction; nanopore platforms continue to improve raw read fidelity and real-time capabilities; and cloud-native bioinformatics is reducing time to answer for oncology, infectious disease, and population health. Meanwhile, regulatory milestones-from U.S. decisions on laboratory-developed tests to new European data rules-are redrawing the contours of clinical adoption. In short, competitive advantage now depends on integrating scientific, operational, and policy signals into coherent execution.

Unpacking transformative shifts reshaping sequencing: long reads, real-time nanopores, multiomics, AI bioinformatics, and rigorous clinical validation

The most consequential shift is the convergence of accuracy, speed, and cost across modalities, enabling end users to select platforms based on biological question rather than historical constraints. Short-read sequencing by synthesis has widened its clinical footprint with higher-fidelity chemistries and software that lift Q-score distributions and reduce PhiX dependency, streamlining counting-based assays and whole-genome runs. Recent platform updates have extended multiomic capability and offered lower-volume, single-flow-cell configurations that lower the hurdle for specialty labs without sacrificing data quality, reflecting a broader push to align instrument tiers with real-world sample volumes and turnaround needs.

Long-read adoption has accelerated from niche to pragmatic utility, particularly where structural variants, repeat expansions, phasing, and methylation matter. Clinical collaborators have reported rare-disease diagnostic gains using highly accurate long reads with integrated detection of complex variants and epigenetic signals, demonstrating potential to replace multi-step workups with a single comprehensive assay and to compress time to diagnosis. These efforts are paired with scaled operations-automated library prep and higher sample batching-that signal readiness for clinical-grade throughput.

Nanopore sequencing continues to blur the line between benchtop and field deployment. Chemistry and basecalling advancements have pushed single-molecule read fidelity into Q20 territory and above, while duplex strategies and software pipelines have tightened consensus accuracy. This has opened routine use of adaptive sampling for targeted enrichment and enabled near-telomere-to-telomere assemblies with simpler compute. Direct RNA improvements and quality-control applications for complex modalities such as mRNA have further broadened use cases in translational and manufacturing environments.

On the informatics side, two movements stand out. First, clinically oriented pipelines are shifting toward turnkey, cloud-delivered stacks with automated variant calling, annotation, and reporting embedded into laboratory information systems. Second, AI-assisted interpretation is being operationalized in tightly controlled workflows for oncology, infectious disease, and hereditary conditions. While AI governance remains in flux across jurisdictions, the direction of travel favors traceability, transparency, and auditability-features increasingly built into commercial bioinformatics offerings.

Regulatory and policy developments are equally transformative. In the United States, the Food and Drug Administration finalized a rule in 2024 that would have phased out general enforcement discretion for laboratory-developed tests over four years. However, a federal court ruling in March 2025 vacated the rule, and the agency has since moved to rescind it, resetting compliance timelines and prompting laboratories to recalibrate investment in submissions and quality systems. Even with this reversal, many organizations continue to align with device-grade documentation and post-market practices to future-proof operations against further policy changes.

Across the Atlantic, the European Health Data Space has entered into force and begins a multi-year transition to harmonize cross-border health data exchange while tightening governance of secondary use, including genetic and genomic data. For sequencing stakeholders, this sets the stage for interoperable data flows, stronger patient rights, and clearer pathways for research access-with meaningful implications for data localization, consent management, and partnerships with European data-access bodies.

Finally, clinical oncology has crossed an important threshold with the approval of comprehensive genomic profiling kits that include pan-cancer companion diagnostic indications. This milestone supports broader decentralization of tumor profiling into regional and community settings and strengthens the business case for in-house sequencing anchored by distributable kits and integrated informatics.

Assessing the cumulative impact of 2025 United States tariffs on sequencing supply, pricing, cross-border trade, and strategic vendor diversification

Trade policy has become a first-order determinant of cost, lead time, and platform choice for sequencing buyers in 2025. The year opened under the shadow of continued Section 301 actions and tariff increases on strategically important inputs announced in late 2024-covering materials such as tungsten products, wafers, and polysilicon effective January 1, 2025-that flow into optics, microelectronics, and specialty components found across instruments, flow cells, and manufacturing equipment. While not aimed specifically at genomics, these measures ripple through upstream supply chains and vendor pricing.

By spring, U.S. executive actions expanded the tariff landscape. A minimum global tariff regime and additional country-specific rates were unveiled, while separate Section 232 proclamations raised duties on steel and aluminum with short notice. Auto and auto-parts tariffs followed. Although these moves were justified under national security and reciprocity frameworks, they added uncertainty to procurement budgets and complicated landed-cost models for imported instruments and lab infrastructure. The administration also issued an order clarifying that overlapping tariff programs should not stack beyond intended policy goals, yet the practical effect for procurement teams has still been net complexity, with country-, category-, and timing-specific exceptions.

The summer brought further changes, including executive action to implement higher country-specific rates beginning in August, reinforcing the need for dynamic sourcing strategies. Suppliers with globally distributed production footprints and multiple distribution centers have been better positioned to buffer customers from shocks; nonetheless, end users have reported the need to widen approved vendor lists for critical consumables and to adjust inventory norms ahead of regulatory-sensitive clinical work.

The most conspicuous flashpoint for sequencing was geopolitical. In March, China banned imports of certain U.S. gene sequencing systems immediately after additional U.S. tariffs took effect, a move that not only limited a major manufacturer's access to a key market but also signaled the possibility of tit-for-tat actions affecting reagents and service workflows. For global labs with cross-border trial cohorts or manufacturing relationships in China, contingency planning moved from theoretical to operational.

Cumulatively, these 2025 tariff dynamics are reshaping category-level economics:

For instruments and platforms, list prices have held steadier than freight and installation costs, but total cost of ownership is rising where components, optics, or electronics are affected by duties. Vendors that introduced single-flow-cell and other lower-volume configurations have inadvertently given buyers more flexibility to stage capacity additions in uncertain budget cycles.

For consumables and reagents, tariffs amplify the value of multi-sourcing and local inventory buffers. Enzymes, buffers, primers, probes, and sequencing kits are susceptible to upstream cost swings in raw materials and packaging. Where import duties touch critical minerals or upstream wafer-based fabrication, knock-on effects can surface in consumable pricing even when final kit assembly is domestic.

For services, contract sequencing providers with diversified geographies can arbitrage tariffs by routing projects through facilities in lower-duty jurisdictions, while maintaining data residency where required. Bioinformatics and data analysis services-less exposed to physical trade-still feel tariff-adjacent effects through hardware import costs and cloud egress strategies that vendors adjust to protect margins.

For software, direct tariff effects are limited, but vendor negotiations increasingly bundle instrument, consumables, and analysis under value-based contracts to smooth duty-driven volatility. This tightens lock-in risk and elevates the importance of interoperability and exit clauses in master agreements.

Overlaying tariffs, the legislative trajectory of the BIOSECURE framework has moved from proposal to an amendment adopted by the U.S. Senate in the annual defense legislation, increasing the likelihood of restrictions on federally funded entities' use of specified foreign-adversary biotechnology firms. Even prior to final enactment, federal grantees are beginning to assess vendor exposure and to document supply-chain provenance-implications that reach sequencing instruments, kits, and data services sourced from or routed through China-affiliated firms.

The practical takeaway is straightforward: duty-driven cost and availability shocks are no longer episodic. Procurement strategies that assume stable tariffs will underperform. Leaders are responding by negotiating indexed pricing, adding regional service providers, increasing safety stocks for clinical-critical consumables, and modeling scenario-based total cost of ownership that incorporates variable duties, shipping, and installation windows.

Decoding key segmentation insights across offerings, technologies, samples, applications, and end users to guide high-confidence portfolio decisions

Viewed through the lens of offerings, the center of gravity continues to shift from standalone instruments toward integrated systems anchored by chemistry, supply continuity, and informatics. While instruments and platforms define core capability, the determinant of real-world utility is increasingly the consumables and reagents stack-enzymes and buffers that stabilize libraries under variable sample quality, primers and probes that support targeted or amplicon-based panels, and full sequencing kits optimized for updated chemistries. Services are being recast as lifecycle partnerships: contract sequencing for burst capacity, bioinformatics and data analysis services that translate raw reads into clinical or research reports, and technical support and maintenance that keep fleets validated under accreditation. Software now ties the system together, from onboard basecalling to cloud-native secondary analysis and reporting, with audit trails that satisfy regulators and payers.

Technologically, the market is no longer a binary short-read versus long-read choice but a toolkit. Next-generation sequencing remains the workhorse, with sequencing by synthesis leading high-throughput and mid-throughput labs, while ion semiconductor sequencing retains relevance in targeted applications that value speed and cost-predictable runs. Third-generation sequencing has stepped into mainstream consideration: long-read platforms are tackling structural variation, repeat expansions, and phasing at scale, and nanopore systems are adding real-time calling and on-instrument enrichment to workflows that once required extensive sample prep. Epigenetic sequencing is moving from research to clinical exploration, with bisulfite sequencing and ChIP sequencing increasingly paired with genomic reads to link sequence to regulation.

Sample diversity is broadening as users pursue comprehensive biology. Human samples-blood; saliva and buccal swabs; urine; cell-free DNA; tissue; and plasma-anchor clinical diagnostics and translational research, with cell-free DNA feeding liquid biopsy pipelines and tissue powering comprehensive genomic profiling. Animal samples now extend beyond model organisms to veterinary diagnostics and livestock genetics. Plant samples-leaf, root, and seed-support trait discovery and breeding programs under climate and pathogen pressure. Microbial samples-bacteria, viruses, fungi, and archaea-drive metagenomics in health, food safety, and industrial bioprocessing. Environmental samples-from wastewater to soil and air-are expanding surveillance and ecological studies.

Applications mirror this breadth. Clinical diagnostics is deepening across oncology, infectious disease diagnosis, rare disease and genetic disorder testing, reproductive health and prenatal testing, and newborn screening, with an emphasis on validated panels and clinical-grade workflows. Research applications still command significant share of activity-genomics and transcriptomics, functional genomics, and epigenetics research-now often combined in multiomic designs. Drug discovery and development users leverage sequencing for biomarker discovery, companion diagnostics, and target identification and validation. Agrigenomics is benefiting from routine plant breeding and trait discovery and from crop pathogen surveillance. Forensics and security continue to invest in human identification, criminal investigation, and disaster victim identification, while environmental and metagenomic studies are shifting from episodic projects to continuous monitoring programs.

End-user patterns reflect this segmentation. Academic and research institutions, including government research institutes and university labs, continue to pioneer novel protocols and large-scale studies that seed downstream clinical adoption. Contract research organizations provide elasticity for sponsors, especially as tariffs and lead times complicate internal capacity planning. Hospitals and diagnostic laboratories are investing in on-premise sequencing where validated kits and streamlined software reduce complexity, while remaining mindful of evolving rules for laboratory-developed testing. Pharmaceutical and biotechnology companies increasingly integrate sequencing across discovery and development, tying biomarker strategies to clinical trial design and companion diagnostic development.

Regional dynamics that matter now: how the Americas, Europe-Middle East-Africa, and Asia-Pacific will shape adoption, access, and compliance

Regional dynamics define opportunity and risk in equal measure. In the Americas, the United States sets the tone for clinical adoption. The 2024 regulatory push to bring laboratory-developed tests under device rules was halted by a federal court in March 2025 and is now being rescinded, injecting both relief and uncertainty. Many hospital and diagnostic laboratories are proceeding with strengthened quality systems and documentation anyway, anticipating that some level of federal or payer-driven standardization will endure. Meanwhile, comprehensive genomic profiling kits with companion diagnostic claims are catalyzing decentralization of oncology testing into community and regional centers, especially as the first wave of adopters demonstrates operational feasibility and payer alignment. Canada and Latin American markets are balancing budget constraints with population genomics ambitions, often leveraging regional service providers to manage cost volatility linked to tariffs and currency.

Across Europe, the Middle East, and Africa, policy clarity is improving due to the European Health Data Space. The regulation's phased implementation provides a roadmap for cross-border access to health data, governance of secondary use, and interoperability expectations for electronic health records. For genomics, the most immediate implications are investments in consent management, data access bodies, and trusted data holders-foundations that will affect how clinical and research sequencing data move within and beyond national borders. In practical terms, organizations planning multicenter studies or pan-European diagnostic offerings will need to align with the EHDS's timetables and technical frameworks. Middle Eastern genomics programs continue to scale capacity through national initiatives, while African centers of excellence build capability via consortia and public-private partnerships that emphasize training, infrastructure, and data sovereignty.

In Asia-Pacific, heterogeneity is the norm. Japan's regulatory environment has welcomed comprehensive genomic profiling tools with local approvals, reinforcing an ecosystem that values precision oncology and coordinated reimbursement policy. China remains a source of innovation and scale but features two-way geopolitical risk: domestic firms are ascendant, and policy actions on both sides of the Pacific have constrained trade in instruments and components, with 2025's import bans and export controls underscoring volatility. Elsewhere, Australia, South Korea, Singapore, and India continue to invest in research infrastructure and translational pipelines, frequently adopting hybrid sourcing models and cloud-forward informatics to manage geography and compliance.

What leading companies signal about the future: platform roadmaps, regulatory milestones, partnerships, and the race for clinical-grade workflows

Recent company-level developments offer a forward look at how competition will unfold. One of the most consequential corporate milestones was the completion of a major divestiture in mid-2024, which removed a regulatory overhang and allowed the core sequencing business to refocus on platform execution and clinical partnerships. The same supplier has since advanced its flagship high-throughput line with a single-flow-cell option, software releases that boost yield and reduce PhiX dependency, and new kits designed for multiomic workloads. Together with its FDA-approved comprehensive genomic profiling kit-an IVD with pan-cancer companion diagnostic claims-this positions the company to serve both centralized and distributed oncology models, from academic hubs to regional systems.

Long-read specialists have translated accuracy gains into clinical collaborations. Publicized studies with European academic medical centers using highly accurate long reads on next-generation instruments have shown that complex structural variants and methylation patterns can be captured alongside small variants, with diagnostic implications for challenging rare disease cases. In parallel, these vendors are scaling manufacturing and sample-throughput capabilities and winning large research awards that signal confidence in long-read modalities for population-scale projects that probe both genome and epigenome.

Nanopore platform providers are delivering continuous chemistry, basecalling, and software improvements that extend utility from field sequencing to regulated labs. Q20-class chemistry, duplex strategies trending toward even higher single-molecule accuracy, enhanced direct RNA runs, and routine adaptive sampling all feed into a broader thesis: real-time, long-fragment sequencing with flexible targeting can be made accessible to non-specialist labs. The steady cadence of technology updates, coupled with growing reference datasets and improved workflows for assembly and targeted calling, is narrowing the performance gap with other modalities while preserving unique advantages in speed and portability.

Challenger short-read vendors are pressing on value and openness. New instruments and chemistry upgrades focus on reducing run cost per read, opening large-scale projects to more institutions and service providers. Some entrants emphasize compatibility with existing library prep and analysis ecosystems, while cultivating certified service networks that offer immediate access without capital outlay-an attractive proposition in tariff-inflated budget cycles.

Across the ecosystem, content suppliers and automation providers-spanning targeted panels, hybrid capture, library prep reagents, and liquid-handling systems-are doubling down on turnkey workflows that reduce hands-on time and variability. Informatics vendors are racing to package variant calling, annotation, reporting, and quality management into auditable pipelines that plug into laboratory information systems and enterprise data lakes. Meanwhile, contract research organizations and certified sequencing service providers are repositioning as end-to-end partners who can absorb tariff risk, meet data-residency obligations, and deliver validated reports under tight timelines.

Actionable guidance for industry leaders: de-risk supply, accelerate evidence, align compliance, and translate sequencing innovation into outcomes

First, treat tariffs as a constant rather than a shock. Build a rolling 18- to 24-month sourcing plan that incorporates scenario-based landed cost models for instruments, flow cells, and consumables, with explicit assumptions about duty rates, shipping, and installation lead times. Add secondary suppliers for critical consumables-primers and probes, enzymes and buffers, and sequencing kits-and negotiate indexed pricing plus contingency clauses that trigger when tariff bands move. For clinical environments, align safety stocks with accreditation and validation cycles to avoid downtime.

Second, adopt a modality-agnostic technology strategy. Maintain at least two complementary platforms-one short-read, one long-read or nanopore-so that structural variants, repeat expansions, targeted panels, and methylation can be addressed in a single laboratory. Where volumes are variable, consider single-flow-cell or mid-throughput systems for everyday operations, reserving high-throughput instruments for batch runs or service partners. Build library preparation and capture workflows that can be shared across platforms to minimize training overhead and consumable complexity.

Third, accelerate clinical evidence generation linked to reimbursement. If you are pursuing oncology, align tumor profiling to FDA-cleared or approved kits where applicable and build prospective utility studies that show time-to-treatment impact and therapy matching-key levers for payer confidence. For rare disease, partner with centers that can combine long-read genome, methylation, and RNA for challenging cases, and publish turnaround time and diagnostic yield under routine conditions.

Fourth, invest in resilient informatics. Standardize on auditable, version-controlled pipelines with provenance tracking from sample intake to report, and design for multi-cloud or hybrid to manage egress fees and data-localization requirements. In Europe, map your data strategy to the European Health Data Space timelines and roles-trusted data holders, access bodies, and interoperability specs-and ensure patient-facing consent and access controls are ready for cross-border use.

Fifth, future-proof compliance. Even with the U.S. LDT rule vacated and in rollback, maintain device-grade documentation, change control, and complaint handling to preserve optionality should policy swing again. Prepare for possible federal funding restrictions on specified foreign-adversary biotech entities by auditing supplier exposure, documenting alternatives, and communicating with grants offices about procurement policies.

Lastly, start with end-user experience. For hospitals and diagnostic laboratories, design workflows for minimal hands-on time and predictable turnaround, backed by on-site technical support and remote monitoring. For academic and government research institutes and university labs, emphasize openness, data portability, and shared compute resources. For CROs and biopharma, link sequencing outputs to biomarker strategies, companion diagnostic timelines, and regulatory submissions to compress cycle times from discovery to development.

How this executive summary was built: rigorous methodology combining primary insight, regulatory review, and cross-validated secondary intelligence

This executive summary synthesizes insights gathered through a mixed-methods approach designed for depth, triangulation, and traceability. Primary research included structured and semi-structured interviews with sequencing platform owners, clinical laboratory directors, academic core facility leaders, translational researchers, CRO executives, and bioinformatics architects across North America, Europe, and Asia-Pacific. These conversations focused on platform selection criteria, run performance under updated chemistries, validation and accreditation practices, procurement constraints created by tariffs and export controls, and the evolving interface between bioinformatics and electronic health records.

Secondary research concentrated on authoritative and timely sources. Regulatory milestones were verified against official publications and agency communications, including U.S. Food and Drug Administration rulemaking, court decisions, and subsequent agency actions related to laboratory-developed tests; European Commission, Council, and Directorate-General communications on the European Health Data Space; and U.S. trade policy updates via the Office of the United States Trade Representative and executive orders. Company-level developments were corroborated using issuer press releases, investor disclosures, and, where relevant, peer-reviewed literature or conference materials. News coverage from global outlets provided contemporaneous context on policy shifts, trade actions, and market responses.

Data synthesis followed a disciplined process. First, we mapped evidence to a segmentation framework spanning offerings; technology type; sample type; applications; and end users. Next, we normalized terminology across sources to avoid conflation of chemistry, platform, and application claims. Finally, we stress-tested conclusions against counter-examples surfaced in interviews and public datasets. No market sizing, share, or forecast figures are presented here; instead, the focus is on qualitative insights with operational implications.

The result is a perspective designed to be both current and durable. Where policies or litigation remain in motion, we anchored statements to dated sources and avoided over-extrapolation. Where technology claims could not be triangulated to independent datasets, we framed them as vendor-reported and evaluated them in the context of end-user experience. This ensures that recommendations can inform decisions now and remain adaptable as new data emerge.

Bringing the narrative together: why sequencing is entering a durable utility phase and how to invest wisely despite volatility and policy shifts

DNA sequencing is entering a durable utility phase. The science has matured to the point where platforms, chemistries, and informatics can be assembled into validated workflows that answer clinical and research questions with speed and accuracy once thought unattainable. Long-read modalities have earned a place alongside short reads; nanopore platforms have expanded beyond field work into regulated workflows; and comprehensive genomic profiling has crossed a regulatory milestone that enables decentralization of oncology testing.

Yet, the operational context is more volatile. Tariffs, export controls, and geopolitical actions have injected persistent uncertainty into cost structures and availability, while data-governance regimes and evolving rules-some advancing, some retreating-require attention to compliance by design. The organizations that will thrive are those that treat supply chain resilience, informatics governance, and clinical evidence as strategic assets, not afterthoughts.

Against this backdrop, leadership teams should move decisively. Adopt a modality-agnostic portfolio to cover the full spectrum of genetic and epigenetic variation. Build informatics that is auditable, portable, and aligned to regional data rules. Prepare for tariff-driven volatility with indexed contracts and multi-sourcing. And, most importantly, translate sequencing into outcomes by investing in the studies, partnerships, and training that deliver answers for patients, growers, public-health officials, and investigators. The opportunity is real and present; the winners will be those who operationalize it with foresight and discipline.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA Sequencing Market, by Offerings

  • 8.1. Consumables & Reagents
    • 8.1.1. Enzymes & Buffers
    • 8.1.2. Primers & Probes
    • 8.1.3. Sequencing Kits
  • 8.2. Instruments & Platforms
    • 8.2.1. DNA Sequencers
    • 8.2.2. Library Preparation Systems
    • 8.2.3. PCR Machines
    • 8.2.4. Flow Cell & Cartridge Hardware
  • 8.3. Services
    • 8.3.1. Contract Sequencing
    • 8.3.2. Bioinformatics & Data Analysis Services
    • 8.3.3. Technical Support and Maintenance
  • 8.4. Software

9. DNA Sequencing Market, by Technology Type

  • 9.1. Next-Generation Sequencing (NGS)
    • 9.1.1. Sequencing by Synthesis
    • 9.1.2. Nanopore Sequencing
    • 9.1.3. Ion Semiconductor Sequencing
  • 9.2. Sanger Sequencing
  • 9.3. Third-Generation Sequencing (TGS)
  • 9.4. Epigenetic Sequencing
    • 9.4.1. Bisulfite Sequencing
    • 9.4.2. ChIP sequencing

10. DNA Sequencing Market, by Sample Type

  • 10.1. Human Samples
    • 10.1.1. Blood
    • 10.1.2. Saliva & Buccal Swab
    • 10.1.3. Urine
    • 10.1.4. Cell-Free DNA
    • 10.1.5. Tissue
    • 10.1.6. Plasma
  • 10.2. Animal Samples
  • 10.3. Plant Samples
    • 10.3.1. Leaf
    • 10.3.2. Root
    • 10.3.3. Seed
  • 10.4. Microbial Samples
    • 10.4.1. Bacteria
    • 10.4.2. Viruses
    • 10.4.3. Fungi
    • 10.4.4. Archaea
  • 10.5. Environmental Samples

11. DNA Sequencing Market, by Application

  • 11.1. Clinical Diagnostics
    • 11.1.1. Oncology
    • 11.1.2. Infectious Disease Diagnosis
    • 11.1.3. Rare Disease & Genetic Disorder Testing
    • 11.1.4. Reproductive Health & Prenatal Testing
    • 11.1.5. Newborn Screening
  • 11.2. Research Applications
    • 11.2.1. Genomics & Transcriptomics
    • 11.2.2. Functional Genomics
    • 11.2.3. Epigenetics Research
  • 11.3. Drug Discovery & Development
    • 11.3.1. Biomarker Discovery
    • 11.3.2. Companion Diagnostics
    • 11.3.3. Target Identification & Validation
  • 11.4. Agrigenomics
    • 11.4.1. Plant Breeding & Trait Discovery
    • 11.4.2. Crop Pathogen Surveillance
  • 11.5. Forensics & Security
    • 11.5.1. Human Identification
    • 11.5.2. Criminal Investigation
    • 11.5.3. Disaster Victim Identification
  • 11.6. Environmental & Metagenomic Studies

12. DNA Sequencing Market, by End User

  • 12.1. Academic & Research Institutions
    • 12.1.1. Government Research Institutes
    • 12.1.2. University Labs
  • 12.2. Contract Research Organizations
  • 12.3. Hospitals & Diagnostic Laboratories
  • 12.4. Pharmaceutical & Biotechnology Companies

13. DNA Sequencing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. DNA Sequencing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. DNA Sequencing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States DNA Sequencing Market

17. China DNA Sequencing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 10x Genomics, Inc.
  • 18.6. Abbott Laboratories
  • 18.7. AbbVie Inc.
  • 18.8. Agilent Technologies, Inc.
  • 18.9. Azenta, Inc.
  • 18.10. Becton, Dickinson and Company
  • 18.11. BGI Genomics Co., Ltd.
  • 18.12. Bio-Rad Laboratories, Inc.
  • 18.13. BioChain Institute Inc.
  • 18.14. Charles River Laboratories International, Inc.
  • 18.15. Danaher Corporation
  • 18.16. Eppendorf SE
  • 18.17. Eurofins Scientific SE
  • 18.18. F. Hoffmann-La Roche Ltd.
  • 18.19. Genomics England
  • 18.20. Genscript Biotech Corporation
  • 18.21. Illumina, Inc.
  • 18.22. Johnson & Johnson Services, Inc.
  • 18.23. Laboratory Corporation of America Holdings
  • 18.24. Macrogen Inc.
  • 18.25. Merck KGaA
  • 18.26. Myriad Genetics, Inc.
  • 18.27. Novartis AG
  • 18.28. Novogene Co, Ltd.
  • 18.29. Oxford Nanopore Technologies PLC
  • 18.30. Pacific Biosciences of California, Inc.
  • 18.31. PerkinElmer, Inc.
  • 18.32. QIAGEN N.V.
  • 18.33. Sartorius AG
  • 18.34. Shimadzu Corporation
  • 18.35. Thermo Fisher Scientific Inc.
  • 18.36. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA SEQUENCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DNA SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA SEQUENCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DNA SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DNA SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DNA SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DNA SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA SEQUENCING MARKET SIZE, BY FLOW CELL & CARTRIDGE HARDWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DNA SEQUENCING MARKET SIZE, BY FLOW CELL & CARTRIDGE HARDWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA SEQUENCING MARKET SIZE, BY FLOW CELL & CARTRIDGE HARDWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA SEQUENCING MARKET SIZE, BY BIOINFORMATICS & DATA ANALYSIS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DNA SEQUENCING MARKET SIZE, BY BIOINFORMATICS & DATA ANALYSIS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA SEQUENCING MARKET SIZE, BY BIOINFORMATICS & DATA ANALYSIS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNICAL SUPPORT AND MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNICAL SUPPORT AND MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNICAL SUPPORT AND MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA SEQUENCING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DNA SEQUENCING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA SEQUENCING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING BY SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING BY SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING BY SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DNA SEQUENCING MARKET SIZE, BY NANOPORE SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA SEQUENCING MARKET SIZE, BY NANOPORE SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DNA SEQUENCING MARKET SIZE, BY NANOPORE SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA SEQUENCING MARKET SIZE, BY ION SEMICONDUCTOR SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DNA SEQUENCING MARKET SIZE, BY ION SEMICONDUCTOR SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA SEQUENCING MARKET SIZE, BY ION SEMICONDUCTOR SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DNA SEQUENCING MARKET SIZE, BY BISULFITE SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DNA SEQUENCING MARKET SIZE, BY BISULFITE SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DNA SEQUENCING MARKET SIZE, BY BISULFITE SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DNA SEQUENCING MARKET SIZE, BY CHIP SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DNA SEQUENCING MARKET SIZE, BY CHIP SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DNA SEQUENCING MARKET SIZE, BY CHIP SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DNA SEQUENCING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DNA SEQUENCING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DNA SEQUENCING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DNA SEQUENCING MARKET SIZE, BY SALIVA & BUCCAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DNA SEQUENCING MARKET SIZE, BY SALIVA & BUCCAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DNA SEQUENCING MARKET SIZE, BY SALIVA & BUCCAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DNA SEQUENCING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DNA SEQUENCING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DNA SEQUENCING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DNA SEQUENCING MARKET SIZE, BY CELL-FREE DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DNA SEQUENCING MARKET SIZE, BY CELL-FREE DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DNA SEQUENCING MARKET SIZE, BY CELL-FREE DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DNA SEQUENCING MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DNA SEQUENCING MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DNA SEQUENCING MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANIMAL SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANIMAL SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANIMAL SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DNA SEQUENCING MARKET SIZE, BY LEAF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DNA SEQUENCING MARKET SIZE, BY LEAF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DNA SEQUENCING MARKET SIZE, BY LEAF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DNA SEQUENCING MARKET SIZE, BY ROOT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DNA SEQUENCING MARKET SIZE, BY ROOT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DNA SEQUENCING MARKET SIZE, BY ROOT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DNA SEQUENCING MARKET SIZE, BY BACTERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DNA SEQUENCING MARKET SIZE, BY BACTERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DNA SEQUENCING MARKET SIZE, BY BACTERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DNA SEQUENCING MARKET SIZE, BY VIRUSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DNA SEQUENCING MARKET SIZE, BY VIRUSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DNA SEQUENCING MARKET SIZE, BY VIRUSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DNA SEQUENCING MARKET SIZE, BY FUNGI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DNA SEQUENCING MARKET SIZE, BY FUNGI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DNA SEQUENCING MARKET SIZE, BY FUNGI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL DNA SEQUENCING MARKET SIZE, BY ARCHAEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL DNA SEQUENCING MARKET SIZE, BY ARCHAEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DNA SEQUENCING MARKET SIZE, BY ARCHAEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENVIRONMENTAL SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENVIRONMENTAL SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENVIRONMENTAL SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL DNA SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL DNA SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL DNA SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL DNA SEQUENCING MARKET SIZE, BY RARE DISEASE & GENETIC DISORDER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL DNA SEQUENCING MARKET SIZE, BY RARE DISEASE & GENETIC DISORDER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL DNA SEQUENCING MARKET SIZE, BY RARE DISEASE & GENETIC DISORDER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL DNA SEQUENCING MARKET SIZE, BY REPRODUCTIVE HEALTH & PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL DNA SEQUENCING MARKET SIZE, BY REPRODUCTIVE HEALTH & PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL DNA SEQUENCING MARKET SIZE, BY REPRODUCTIVE HEALTH & PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENOMICS & TRANSCRIPTOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENOMICS & TRANSCRIPTOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENOMICS & TRANSCRIPTOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL DNA SEQUENCING MARKET SIZE, BY FUNCTIONAL GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL DNA SEQUENCING MARKET SIZE, BY FUNCTIONAL GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL DNA SEQUENCING MARKET SIZE, BY FUNCTIONAL GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL DNA SEQUENCING MARKET SIZE, BY EPIGENETICS RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL DNA SEQUENCING MARKET SIZE, BY EPIGENETICS RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL DNA SEQUENCING MARKET SIZE, BY EPIGENETICS RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL DNA SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL DNA SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL DNA SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL DNA SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL DNA SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL DNA SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL DNA SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL DNA SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL DNA SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLANT BREEDING & TRAIT DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLANT BREEDING & TRAIT DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLANT BREEDING & TRAIT DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL DNA SEQUENCING MARKET SIZE, BY CROP PATHOGEN SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL DNA SEQUENCING MARKET SIZE, BY CROP PATHOGEN SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL DNA SEQUENCING MARKET SIZE, BY CROP PATHOGEN SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL DNA SEQUENCING MARKET SIZE, BY HUMAN IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL DNA SEQUENCING MARKET SIZE, BY HUMAN IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL DNA SEQUENCING MARKET SIZE, BY HUMAN IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL DNA SEQUENCING MARKET SIZE, BY CRIMINAL INVESTIGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL DNA SEQUENCING MARKET SIZE, BY CRIMINAL INVESTIGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL DNA SEQUENCING MARKET SIZE, BY CRIMINAL INVESTIGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL DNA SEQUENCING MARKET SIZE, BY DISASTER VICTIM IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL DNA SEQUENCING MARKET SIZE, BY DISASTER VICTIM IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL DNA SEQUENCING MARKET SIZE, BY DISASTER VICTIM IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENVIRONMENTAL & METAGENOMIC STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENVIRONMENTAL & METAGENOMIC STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENVIRONMENTAL & METAGENOMIC STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL DNA SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS DNA SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 240. AMERICAS DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 241. AMERICAS DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. AMERICAS DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 243. AMERICAS DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 244. AMERICAS DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 245. AMERICAS DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 246. AMERICAS DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 247. AMERICAS DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. AMERICAS DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 260. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 264. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 266. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 280. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 284. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 286. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPE DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPE DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPE DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPE DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPE DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPE DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPE DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 316. EUROPE DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPE DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. EUROPE DNA SEQUENCING MARKET SIZE, BY HUMAN SA